- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01554020
Blood Sugar Take Care and Glucose Metabolism
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94109
- SPRIM
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
SUBJECT INCLUSION CRITERIA: STEP 1
- Age ≥ 18 years
Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- Have a first-degree relative with diabetes
- Habitually physically inactive
- Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- Hypertensive (≥140/90)
- Known HDL cholesterol level 35 mg/dl
- Known triglyceride level ≥250 mg/dl
- On previous testing, had impaired glucose tolerance or impaired fasting glucose
- History of vascular disease
- Stable body weight (<5% change) in the last 3 months
- Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- Able to understand the nature and purpose of the study including potential risks and side effects
- Willing to consent to study participation and to comply with study requirements
SUBJECT EXCLUSION CRITERIA
- Known diabetes (type I or II)
- Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- Eating disorder
- Polycystic ovary syndrome
- Known allergies to any substance in the study product
- Pregnant or breastfeeding women
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
SUBJECT INCLUSION CRITERIA: STEP 2
1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
SUBJECT INCLUSION CRITERIA: STEP 3
- Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Multiherb product
Herbal product
|
One 1200 mg soft gel capsule administered 3X/day for duration of study
Andra namn:
|
|
Placebo-jämförare: Placebo
Maltodextrin control
|
One 1200 mg soft-gel capsule administered 3X/day for duration of study
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Fasteglukos
Tidsram: 12 veckor
|
12 veckor
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Biverkningar
Tidsram: 12 veckor
|
12 veckor
|
|
|
Blodtryck
Tidsram: 12 veckor
|
12 veckor
|
|
|
Insulinkänslighetsindex
Tidsram: 12 veckor
|
12 veckor
|
|
|
Fastande insulin
Tidsram: 12 veckor
|
12 veckor
|
|
|
Homeostasis Model Assessment of Insulin Resistance
Tidsram: 12 weeks
|
12 weeks
|
|
|
Quantitative insulin sensitivity check index
Tidsram: 12 weeks
|
12 weeks
|
|
|
Insulin secretion/insulin resistance index
Tidsram: 12 weeks
|
12 weeks
|
|
|
Glykosylerat hemoglobin (HbA1c)
Tidsram: 12 veckor
|
12 veckor
|
|
|
High-sensitivity C-reactive protein
Tidsram: 12 weeks
|
12 weeks
|
|
|
High-molecular weight adiponectin
Tidsram: 12 weeks
|
12 weeks
|
|
|
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
Tidsram: 12 weeks
|
12 weeks
|
|
|
Body composition
Tidsram: 12 weeks
|
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
|
12 weeks
|
|
WHO Quality of Life Questionnaire
Tidsram: 12 weeks
|
12 weeks
|
|
|
Comprehensive metabolic panel
Tidsram: 12 weeks
|
12 weeks
|
|
|
Fullständigt blodvärde
Tidsram: 12 veckor
|
12 veckor
|
|
|
Gastrointestinal Symptom Rating Scale
Tidsram: 12 weeks
|
12 weeks
|
|
|
Pulse
Tidsram: 12 weeks
|
12 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Larry Miller, PhD, Sprim Advanced Life Sciences
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 120216-SUS-NWC-BSS-GP
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .